EFPIA Unveils Action Plan for Lithuania
The Lithuanian Ministry of Health and EFPIA have announced a new Joint Working Agreement.
The Lithuanian Ministry of Health and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have announced a new Joint Working Agreement that paves the way for protecting future health and growth in Lithuania.
The agreement is a concrete step towards delivering the vision of health and sustainable growth set out in the Vilnius Declaration, which was signed during Lithuania's Presidency of the EU last year, according to EFPIA. It sets out a series of measures to safeguard future innovation and healthcare, including establishing a specific ‘Reimbursement Budget’ that will reflect and be proportionate to both gross domestic product (GDP) growth and increase in overall public health care spending.
“We are creating a sustainable health care system that is prone to demographic and economic challenges, that promptly responds to current health threats, that incorporates newest technologies and best medical practices,” said Lithuanian Minister of Health Vytenis Povilas Andriukaitis. “The Ministry of Health and EFPIA working together means new treatment options for the patients, greater transparency for the healthcare industry and meaningful cooperation with innovative businesses.”
Through partnering on a holistic life sciences strategy, EFPIA and the Lithuanian Ministry of Health hope to make Lithuania a more attractive location for life sciences investment, and to support a healthy population through the creation of more effective, efficient and sustainable health systems.
According to EFPIA Director General Richard Bergström: “Our industry has entered into a number of agreements with European governments, but the Lithuanian agreement has achieved a new progressive, gold standard in collaboration for better health outcomes. It signifies a new dawn in our industry’s partnerships, as it delivers a much more comprehensive solution to meeting the health and economic needs of citizens. I urge other nations to learn from the Lithuanian approach.”
Such collaborative efforts are part of EFPIA’s recently launched strategy, “Health and Growth: Working together for a healthy Europe,” which advocates for an integrated life sciences sector for the EU.
Read the full announcement here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
